515.2 (asbestosis) for years [1968][1969][1970][1971][1972][1973][1974][1975][1976][1977][1978], ICD-9 code 501 (asbestosis) for years 1979-1998, and ICD-10 code J61 (pneumoconiosis due to asbestos and other mineral fibers) for years 1999 -2005 . For years 1999 -2005 , decedents with ICD-10 underlying cause coded as J65 (pneumoconiosis associated with tuberculosis) or J92.0 (pleural plaque with presence of asbestos) also were included in the underlying cause-of-death tabulation for asbestosis if code J61 also was listed on the death certificate.
Exposure to asbestos fibers can cause asbestosis and other diseases (1) after a latency of 10-40 years from initial exposure to onset of illness. Asbestos still is used in the United States (approximately 2,200 metric tons in 2006) in certain products manufactured domestically (2) . In addition, an undocumented amount of asbestos continues to be imported in products manufactured elsewhere, and a substantial amount of asbestos remains in existing buildings and manufactured products. An estimated 1.3 million construction and general industry workers in the United States potentially are exposed to asbestos each year, mainly from manipulation of asbestos during renovation or demolition activities (3) . Also, although asbestos ore is no longer mined in the United States (4), some U.S. mine workers might remain at risk for exposure to asbestos contained in other ores. To characterize trends in premature mortality attributed to asbestosis in the United States, CDC analyzed annual underlying cause-of-death data for 1968-2005, the most recent years for which data were available.* This report describes the results of that analysis, which indicated that annual years of potential life lost before age 65 years (YPLL) attributed to asbestosis increased 64%, from an average of 146.0 YPLL per year during 1968-1972 to 239.6 per year during 2001-2005 (regression trend for the 5-year moving average, p<0.001), for an overall total of 7,267 YPLL (mean per decedent: 6.2) over the entire period. These results demonstrate that asbestosis-attributable YPLL continue to occur and that efforts to prevent, track, and eliminate asbestosis need to be maintained.
For this analysis, decedents for whom the International Classification of Diseases (ICD) code for asbestosis was listed as the underlying cause of death were identified from 1968-2005 mortality data. † Given the occupational etiology and long latency of asbestosis, analysis was restricted to deaths of persons aged >25 years. Standard industry and occupation information that met CDC quality criteria was available for decedents in 26 states during the 1985-1999 period. § After 1999, funds for coding industry and occupation were not available, and coding at the state level ceased. The number of states reporting data in any particular year varied from 16 to 22, and the number of years of data available for any one state varied from 2 to 15. Industry and occupation were classified according to two U.S. Census Bureau coding systems. ¶ YPLL and mean YPLL were calculated using 5-year age groups and standard methodology (5) . A simple linear regression model was used for time-trend analysis of YPLL (using 5-year moving averages).
During 1968-2005, asbestosis was identified as the underlying cause of death for 9,024 decedents. Of these, 1,169 (13.0%) were aged 25-64 years, including one (0.1%) decedent aged 25-34 years; 17 (1.5%) aged 35-44 years; 165 (14.1%) aged 45-54 years; and 986 (84.3%) aged 55-64 years, accounting for 7,267 YPLL (mean per decedent: 6.2). The majority of asbestosis decedents aged 25-64 years were male (1, 125 [96.2%]) and white (1,064 [91.0%]), accounting for 7,038 (96.8%) and 6,470 (89.0%) YPLL, respectively (Table 1) .
YPLL attributed to asbestosis deaths increased 64%, from an average of 146.0 per year during [1968] [1969] [1970] [1971] [1972] (Table 1) .
Industry and occupation information was available for 153 (28.8%) of the 531 decedents aged 25-64 years with asbestosis as the underlying cause of death during [1985] [1986] [1987] [1988] [1989] [1990] [1991] [1992] [1993] [1994] [1995] [1996] [1997] [1998] [1999] (Table 2) . Of 54 industries reported, the greatest YPLL were in construction (244 YPLL; mean per decedent: 5.7); ship and boat building and repairing (41; mean per decedent: 5.9); and military (41; mean per decedent: 5.9). Of 59 occupations reported, the greatest YPLL were for insulation workers (112; mean per decedent: 5.9); managers and administrators, not elsewhere classified (43; mean per decedent: 7.2); and plumbers, pipefitters, and steamfitters (42; mean per decedent: 4.7).
age 65 years are considered as having years of potential work tenure lost, on the assumption that these are a worker's most productive years. During 1968-2005, asbestosis was identified as the underlying cause of death for 1,169 decedents aged 25-64 years, accounting for 7,267 YPLL. Overall, a mean of 6.2 YPLL per decedent was attributed to asbestosis during 1968-2005, indicating that, on average, decedents aged 25-64 years with asbestosis listed as the underlying cause of death died at age 58 years. Despite the decline in asbestos use and reduced exposures, the findings described in this report indicate that asbestosis-attributable YPLL continue to occur. Because asbestosis mortality typically manifests several decades after initial exposure to asbestos, much of the continuing YPLL likely is attributed to exposures experienced decades ago. During 1970 During -2004 , the annual number of asbestosis-related deaths (based on the analysis of asbestosis deaths coded on the entity axis in multiple cause-of-death files**) in the United States increased nearly 17-fold, from 89 (age-adjusted death rate: 0.6 per million persons aged >15 years) in 1970 to 1,493 (6.9) in 2000, and then declined slightly to 1,470 (6.3) in 2004, for an overall total of 25,413 asbestosis deaths over the entire period (7) . This slight decline in the age-adjusted death rate was attributed to several factors, including reduced use of asbestos and improved control of asbestos exposure (8,9). Beginning several decades ago, increased awareness of the health consequences of asbestos exposure stimulated voluntary and regulatory actions by the Environmental Protection Agency and the Occupational Safety and Health Administration (8,9). Available data (for 153 decedents) indicated that the greatest industry-specific YPLL values were associated with work in construction and ship and boat building and repairing, which is consistent with documented past industry-specific asbestos exposures (1) . Likewise, two of the three occupations with the greatest YPLL values, insulation workers and plumbers, pipefitters, and steamfitters, are well known to have been associated with asbestos exposures.
The findings in this report are subject to at least six limitations. First, this report used a death certificate-based definition of asbestosis as the underlying cause of death. Because some deaths from asbestosis might have been attributed to other diseases (e.g., idiopathic pulmonary fibrosis) instead of to asbestosis, the findings in this report likely underestimate deaths and YPLL attributable to asbestosis. Second, complete work histories are not listed on death certificates, and the relevance of the reported usual industry and occupation to actual hazardous exposures could not be verified. Although no studies have examined the accuracy of usual industry and occupation information on death certificates specifically for asbestosis decedents, research suggests a generally good agreement of this information compared with that from other sources (10). Third, coded information on usual industry and occupation were available for decedents in only 26 states, accounting for 28.8% of all U.S. asbestosis decedents during 1985-1999. Thus, these data might not be nationally representative for [1985] [1986] [1987] [1988] [1989] [1990] [1991] [1992] [1993] [1994] [1995] [1996] [1997] [1998] [1999] . Fourth, the state issuing a death certificate is not always the state in which the decedent's asbestos exposure occurred. Fifth, ICD cause-of-death codes used in this analysis changed twice during 1968-2005. However, these revisions likely did not introduce bias or affect the temporal trend in asbestosis deaths (7) . Finally, YPLL, as calculated, do not account for the full burden of asbestosis. During the period for which CDC analyzed U.S. death data, approximately 87% of the deaths with asbestosis listed as the underlying cause of death occurred in persons aged >65 years. Moreover, although YPLL do reflect premature mortality during the most productive years of life, YPLL do not account for all reduced quality of life or work years lost attributed to disability from asbestosis. Persons with asbestosis can live for many years with severely limited lung function and few treatment options, leading to inability to work.
The continuing occurrence of cases of asbestos in younger persons (asbestosis-attributable YPLL) underscores the need for persistent asbestosis prevention and elimination efforts. Effective primary prevention is critical because asbestos-related diseases can develop or progress even after occupational exposure ends. Guidance for persons concerned about exposure to asbestos and for health-care providers who work with patients potentially exposed to asbestos is available at http://www.cdc. gov/health/asbestos.htm. CDC continues to conduct surveillance for asbestosis and other asbestos-related deaths to follow trends and identify problems. from completion of a diagnostic laboratory test to notification of the county health department (CHD) of the result. This report summarizes the results of that analysis, which showed that ELR would reduce the total time from symptom onset to CHD notification of a case by nearly half for salmonellosis (from 12 days to 7 days) and shigellosis (from 10 days to 6 days), but would produce no change for meningococcal disease (4 days) and minimal improvement for hepatitis A (from 13 days to 10 days). In Florida, the benefits of ELR for reporting timeliness likely will vary by disease. The FDOH web-based reportable disease surveillance database (Merlin) was used to conduct this evaluation. The Florida Bureau of Epidemiology annually receives from CHDs approximately 30,000 reports of cases of notifiable infectious diseases. With full implementation of ELR, participating laboratories will transmit electronically all reportable laboratory results directly to Merlin, which can then be accessed by all CHD epidemiologists. To evaluate the potential of ELR to change the timeliness of disease reporting in Florida, FDOH investigators selected four key notifiable diseases, either because of high severity or significant public health concern: salmonellosis, shigellosis, meningococcal disease, and hepatitis A. Confirmed cases of the four diseases were analyzed for the study period, 2002 -2006 . Florida began implementation of ELR from commercial laboratories in 2006, but ELR was not in use for any of the four diseases included in this analysis during the study period.
The regular practice during the study period was for CHD epidemiologists to manually enter all data for the four diseases into Merlin, including dates of symptom onset (as reported by patients), laboratory reporting, and CHD notification. Symptom onset date was defined as the date of illness reported by patient. Laboratory reporting date was the date the laboratory report was mailed, faxed, or conveyed to the CHD by telephone. CHD notification date was the date the CHD recorded receipt of the laboratory report. However, all three date fields were not required for a final case report to be submitted through Merlin to FDOH. Three time intervals were calculated: symptom onset date to laboratory reporting date (interval A), laboratory reporting date to CHD notification date (interval B), and symptom onset date to CHD notification date (interval C). Next, the percentage of cases reported within one and two incubation periods for each disease was calculated. Incubation period was used as a proxy for period of transmissibility (3). The incubation period for each of the four diseases (1 day for salmonellosis, 3 days for shigellosis, 4 days for meningococcal disease, and 30 days for hepatitis A) was assumed to be the midpoint of the range most commonly reported in the literature (4, 5) . Although the electronic transmission of laboratory reports is instantaneous, interval B was assumed to be 1 day when ELR was implemented because many laboratories batch their electronic reporting once per shift or once per day.
Among the 23,263 confirmed cases of salmonellosis reported during the 5-year period, 81% of reports included symptom onset date, 72% included laboratory reporting date, and 96% included CHD notification date. Time intervals A, B, and C could be calculated for 57%, 68%, and 78% of cases, respectively ( Table 1 ). The median number of days for intervals A, B, and C were 6, 5, and 12, respectively ( Table 2) . If ELR were used for salmonellosis reporting, interval B would decrease from 5 days to 1 day, which would result in a decrease of interval C (symptom onset date to CHD notification date) from 12 to 7 days (Table 2, Figure) . The percentage reported within two incubation periods would increase from 1% to 10%. Reporting within two incubation periods would improve from 28% to 60% for shigellosis, from 84% to 94% for meningococcal disease, and from 92% to 98% for hepatitis A (Table 2) . Editorial Note: Investments in ELR systems for notifiable diseases generally are justified by expected improvements in timeliness and sensitivity of reporting. This analysis determined that, in Florida, improvements in timeliness in reporting would be highly disease specific. The greatest improvements in timeliness of reporting (i.e., the absolute number of days for CHDs to be notified of illness) would be expected for salmonellosis and shigellosis. In Florida, these two diseases often are reported by postal mail. With implementation of ELR, the reporting time from symptom onset to CHD notification would be nearly halved. These two diseases also would experience the greatest increase in timeliness of reporting within two incubation periods, in part because they have the shortest incubation periods of the four diseases tested in this analysis (1 and 3 days, respectively). When laboratory reports for a condition with a short incubation period are mailed from laboratory to CHD, only a small fraction of cases are reported to CHDs within two incubation periods. Results for meningococcal disease and hepatitis A, which have longer incubation periods, often are reported from laboratories by faster methods (fax or telephone). Because clinicians, laboratorians, and health departments already place great importance on timely reporting of meningococcal disease, more cases are reported within two incubation periods and the potential improvement with use of ELR is less. Under the assumptions of this analysis, the median number of days to report laboratory results to a CHD for meningococcal disease (1 day) would not change. In addition to timeliness, the completeness of reporting dates will improve for all conditions reported with ELR, approaching 100% for the laboratory reporting and CHD notification dates, which will be required fields automatically populated by ELR software. This information will permit time intervals to be more completely calculated. The date of symptom onset and any time interval using this date are, however, dependent on patient recall and not on programming of surveillance system software. 
Salmonellosis
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The findings in this report are subject to at least three limitations. First, depending on the disease and category of date, from 1% to 33% of key dates were missing from the Merlin database (Table 1) . Results might have differed if all such dates had been available for all cases. Second, interpretation and application of date field definitions by those entering data into Merlin vary, and this might lead to inconsistent data entry practices. Finally, Merlin does not allow for recording times in less than 1-day increments; thus, shorter intervals for reporting laboratory results could not be assessed.
This analysis did not assess directly the potential effect of ELR on the workload of CHD communicable disease investigators in Florida. However, the implementation of ELR likely will have some effects. For example, most cases of meningococcal disease in Florida are reported quickly to FDOH and intensively investigated under the existing reporting system. Thus, the number of cases of meningococcal disease requiring investigation is not likely to increase with ELR. However, for salmonellosis, shigellosis, and hepatitis A, an increase in reported cases is anticipated with ELR, because all positive cultures and immunoglobulin (IgM) results will be transmitted electronically. Under the existing system, in 2005, 84% of hospitalized salmonellosis patients were recorded in the Merlin database, 73% of hospitalized shigellosis patients, and 52% of hospitalized hepatitis A patients. If ELR captures more cases than currently are entered into Merlin manually, the workload of county and state health staff will increase. For some reportable conditions (e.g., hepatitis A), a large amount of clinical information and additional laboratory data often is required to confirm the diagnosis after a laboratory report is received. Much of this information is not included among the ELR data but is needed to classify the case according to the case definition. The implementation of ELR might cause an increase in the number of preliminary reports that must be investigated, thus increasing workload, without a corresponding increase in the number of confirmed cases (6, 7) .
ELR is being introduced in Florida in a stepwise fashion, with laboratory facilities brought on incrementally rather than all at once. This is allowing CHDs to assess the effects of ELR on workflow and human resource requirements for various reportable diseases. The analysis in this report suggests the effects of ELR will be disease specific, with differing limitations and challenges for each condition. Under a newly implemented ELR system, local and state public health officials should be able to 1) monitor timeliness and completeness of reporting, 2) assess workload and workflow, 3) ensure that reporting of high-priority conditions is not adversely affected by ELR, and 4) interact with clinicians in a manner that fosters respect for the clinician-patient relationship and compliance with statemandated reporting requirements. If the number of reported cases increases substantially when ELR is implemented, jurisdictions will need to establish priorities for investigation and follow-up of laboratory reports received (6) . 
Antiviral Resistance of Influenza Virus Isolates
With limited influenza activity in the United States, few viruses have been available for antiviral resistance testing. Since September 28, 2008, 39 influenza viruses from 11 states have been tested for antiviral resistance; of the viruses tested, 28 (71.8%) were collected from only two states. Preliminary data show that 24 of the 25 influenza A (H1N1) isolates tested were resistant to oseltamivir; all H1N1 isolates were sensitive to zanamivir. All five influenza A (H3N2) and the nine influenza B isolates tested were sensitive to oseltamivir and zanamivir. Twenty-five influenza A (H1N1) isolates and five influenza A (H3N2) isolates were tested for adamantane resistance. All influenza A (H1N1) isolates were sensitive to adamantanes, and all influenza A (H3N2) isolates tested were resistant to adamantanes. The adamantanes are not effective against influenza B viruses.
Currently, data on antiviral resistance, and information on which influenza virus types or subtypes will circulate, are insufficient to provide an indication of the prevalence of antiviral resistance at a national or regional level during this season. CDC has solicited a representative sample of viruses from WHO collaborating laboratories in the United States for resistance testing throughout the season, and more specimens are expected as influenza activity increases.
Novel Influenza A Viruses
One case of human infection with a novel influenza A virus was reported from Texas during the week ending November 15, 2008. A child aged 14 years was infected with swine influenza A (H1N1) in October 2008 after several reported swine exposures. The child recovered from the illness, and no contacts of the child were reported to be ill.
State-Specific Activity Levels
For the week ending November 29, 2008, influenza activity † was reported as sporadic in Puerto Rico and 22 states, and one * The CDC influenza surveillance system collects five categories of information from 10 data sources. 
Outpatient Illness Surveillance
Since September 28, 2008, the weekly percentage of outpatient visits for influenza-like illness (ILI) § reported by approximately 1,500 U.S. sentinel providers in 50 states, New York City, Chicago, and the District of Columbia that comprise the U.S. Outpatient ILI Surveillance Network (ILINet), has ranged from 0.9% to 1.3% (Figure 2 ). This is below the national baseline of 2.4%. In addition, all nine surveillance regions reported percentages below their respective regionspecific baselines. ¶
Pneumonia-and Influenza-Related Mortality
For the week ending November 29, 2008, pneumonia and influenza (P&I) was reported as an underlying or contributing cause of death for 6.7% of all deaths reported to the 122 Cities Mortality Reporting System. This is below the epidemic threshold of 7.1% for that period. Since September 28, 2008, the weekly percentage of deaths attributed to P&I ranged from 6.0%-6.7%, remaining below the epidemic threshold.**
Influenza-Associated Pediatric Hospitalizations
Pediatric hospitalizations associated with laboratoryconfirmed influenza infections are monitored by two population-based surveillance networks, the Emerging Infections Program (EIP) and the New Vaccine Surveillance Network (NVSN). No influenza-associated pediatric hospitalizations have yet been reported by either network this season.
Influenza-Related Pediatric Mortality
No influenza-related pediatric deaths have been reported for the 2008-09 season. Editorial Note: During September 28-November 29, 2008, the United States experienced a low level of influenza activity which is typical for this time of year and similar to the past four influenza seasons. The peak of influenza activity has come 8°C) , oral or equivalent, and cough and/or sore throat, in the absence of a known cause other than influenza. ¶ The national and regional baselines are the mean percentage of visits for ILI during noninfluenza weeks for the previous three seasons plus two standard deviations. A noninfluenza week is a week during which <10% of specimens tested positive for influenza. National and regional percentages of patient visits for ILI are weighted on the basis of state population. Use of the national baseline for regional data is not appropriate. ** The seasonal baseline proportion of P&I deaths is projected using a robust regression procedure in which a periodic regression model is applied to the observed percentage of deaths from P&I that were reported by the 122 Cities Mortality Reporting System during the preceding 5 years. The epidemic threshold is 1.645 standard deviations above the seasonal baseline. However, these viruses were isolated in few states and early in the influenza season; CDC will test more viruses as flu activity increases and more samples become available. The season has not progressed enough to determine which influenza virus type or subtype will predominate this season.
On average, influenza is estimated to cause approximately 226,000 hospitalizations and 36,000 deaths per year in the United States. Annual vaccination remains the best method for preventing influenza and its potentially severe complications. The Advisory Committee on Immunization Practices (ACIP) recently expanded its recommendations for influenza vaccination to include all children aged 6 months-18 years. In addition, influenza vaccine should be administered to other persons at high risk for influenza-related complications, close contacts of those at high risk (including health-care workers), and anyone else who wants to decrease their risk for influenza (2) . Enhanced surveillance for oseltamivir-resistant viruses is ongoing at CDC. Alternatives for antiviral treatment in the context of widely circulating oseltamivir-resistant viruses have been suggested. These treatment options, which might include preferential use of zanamivir or therapy with a combination of antivirals for certain patients, have been outlined in the ACIP 2008 influenza recommendations. † † Currently, the neuraminidase inhibitors oseltamivir and zanamivir remain the recommended medications for treatment and chemoprophylaxis of influenza.
Clinicians should remain alert for changes in recommendations that might occur as the 2008-09 influenza season progresses. Recommendations regarding the use of antiviral medications might be revised if surveillance data indicate a substantial and widespread increase in the prevalence of oseltamivir-resistant influenza viruses in the United States.
Vaccination remains the cornerstone of influenza prevention efforts. Influenza vaccination can prevent influenza infections from strains that are sensitive or resistant to antiviral medications; the influenza A (H1N1) viruses found to be oseltamivir resistant are antigenically similar to the components included 
Notice to Readers
Publication of World Report on Child Injury Prevention
Child injuries are a growing global public health problem. Worldwide each year, approximately 10-30 million persons aged <18 years are injured, and 875,000 die from their injuries (1,2). Moreover, 95% of these injuries occur in low-and middle-income countries (1 (3) . Each mechanism is reviewed according to its epidemiology, known risk factors, existing interventions and their effectiveness, and strategies to prevent or manage the particular type of injury. The report documents what is known about child and adolescent injuries worldwide and how these injuries can be prevented.
In the United States each year, approximately 12,000 deaths and an estimated 9.2 million nonfatal unintentional injuries are reported among persons aged <19 years (4); unintentional injuries are the leading cause of death among those aged 1-19 years (4, 5) . Creating a safe environment, adopting and enforcing stringent safety laws, improving product safety, educating parents, and encouraging behavior change are all important in the prevention of injuries in children. Information regarding U.S. data and efforts to prevent child injuries, including the CDC Childhood Injury Report, is available at http://www.cdc. gov/safechild. Other tools at this site include fact sheets, podcasts, and state-specific data on the leading causes of child and adolescent injury, and how these injuries can be prevented. 
Notice to Readers
Pre-Beta Version of Open Source Epi Info Released
CDC has released a pre-beta version of the Epi Info™ Community Edition for developers and information technology professionals who wish to contribute enhancements and features. This release represents the beginning of a rewrite of the Epi Info suite of tools into the C#.net development Overall, 20.4% of adults aged >18 years had five or more alcoholic drinks in 1 day at least once in the preceding year. For both men and women, the percentage decreased with age. In all four age groups, men were substantially more likely than women to have had five or more drinks in 1 day at least once in the preceding year. 
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December 12, 2008 Table II . ** The names of the reporting categories changed in 2008 as a result of revisions to the case definitions. Cases reported prior to 2008 were reported in the categories: Ehrlichiosis, human monocytic (analogous to E. chaffeensis); Ehrlichiosis, human granulocytic (analogous to Anaplasma phagocytophilum), and Ehrlichiosis, unspecified, or other agent (which included cases unable to be clearly placed in other categories, as well as possible cases of E. ewingii). † † Data for H. influenzae (all ages, all serotypes) are available in Table II . § § Updated monthly from reports to the Division of HIV/AIDS Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention. Implementation of HIV reporting influences the number of cases reported. Updates of pediatric HIV data have been temporarily suspended until upgrading of the national HIV/AIDS surveillance data management system is completed. Data for HIV/AIDS, when available, are displayed in Table IV , which appears quarterly. ¶ ¶ Updated weekly from reports to the Influenza Division, National Center for Immunization and Respiratory Diseases. There are no reports of confirmed influenza-associated pediatric deaths for the current 2008-09 season. *** The one measles case reported for the current week was indigenous. † † † Data for meningococcal disease (all serogroups) are available in Table II . § § § In 2008, Q fever acute and chronic reporting categories were recognized as a result of revisions to the Q fever case definition. Prior to that time, case counts were not differentiated with respect to acute and chronic Q fever cases. ¶ ¶ ¶ No rubella cases were reported for the current week. **** Updated weekly from reports to the Division of Viral and Rickettsial Diseases, National Center for Zoonotic, Vector-Borne, and Enteric Diseases. * Ratio of current 4-week total to mean of 15 4-week totals (from previous, comparable, and subsequent 4-week periods for the past 5 years). The point where the hatched area begins is based on the mean and two standard deviations of these 4-week totals. -2  7  101  128  -1  7  60  121  3  2  16  125  150  Connecticut  -0  4  26  25  -0  7  23  38  3  0  5  41  38  Maine  §  -0  2  11  5  -0  2  11  15  -0  2  9  9  Massachusetts  -0  5  38  65  -0  1  9  42  -0  3  13  47  New Hampshire  -0  2  12  12  -0  2  11  5  -0  5  27  8  Rhode Island  §  -0  2  12  13  -0  1  4 -4  55  188  255  5  12  131  591  893  -1  23  70  130  Arkansas  §  -0  1  5  12  -0  4  30  69  -0  2  11  15  Louisiana  -0  1  10  27  -1  4  73  95  -0  2  9  6  Oklahoma  -0  3  7  10  4  2  22  109  127  -0  6  10  6  Texas  §  -3  53  166  206  1  7  107  379  602  -1  18  40  103  Mountain  1  4  12  195  216  1  4  10  181  204  1  2  7  77  105  Arizona  1  2  11  99  144  -1  5  63  80  1  0  2  20  37  Colorado  -0  3  35  24  -0  3  30  35  -0  2  10  21  Idaho  §  -0  3  18  8  -0  2  8  14  -0  1  3  6  Montana  §  -0  1  1  9  -0  1  2  --0  1  4  3  Nevada  §  -0  3  9  11  1  1  3  33  46  -0  2  10  9  New Mexico  §  -0  3  17  11  -0  2  11  12  -0  1  7  10  Utah  -0  2  13  6  -0  5  30  12  -0  2  23  16  Wyoming  §  -0  1  3  3  -0  1  4  5  -0  0  -3  Pacific  2  11  51  508  619  4  7  30  342  496  4  4  18  217  121  Alaska  -0  1  3  4  -0  2  9  9  -0  1  2  -California  2  9  42  417  531  3  5  19  243  364  4  3  14  175  88  Hawaii  -0  2  17  7  -0  1  7  16  -0  1  8  2  Oregon  §  -0  3  25  28  -1  3  39  57  -0  2  15  12  Washington  -1  7  46  49  1  1  9  44  50  -0  3  17  19  American Samoa  -0 -0  3  10  13  -0  1  4  6  -0  2  10  9  Kentucky  -0  2  5  6  -0  1  5  9  -0  2  8  12  Mississippi  -0  1  1  1  -0  1  1  2  1  0  2  12  11  Tennessee  §  1  0  3  30  31  -0  2  10  20  -0  3  21  17  W.S. Central  -2  11  97  77  2  1  64  76  86  3  2  13  108  95  Arkansas  §  -0  0  -1  -0  0  -2  2  0  2  14  9  Louisiana  -0  1  3  2  -0  1  3  14  -0  3  22  25  Oklahoma  -0  1  --2  0  4  4  5  -0  5  17  16  Texas  §  -2  10  94  74  -1  60  69  65  1  1  7  55  45  Mountain  -0  4  41  45  -1  3  30  63  -1  4  50  64  Arizona  -0  2  8  2  -0  2  14  12  -0  2  9  12  Colorado  -0  2  7  --0  1  4  23  -0  1  14  21  Idaho  §  -0  2  9  9  -0  1  3  5  -0  1  4  7  Montana  §  -0  1  4  4  -0  0  -3  -0  1  5  2  Nevada  §  -0  2  4  15  -0  3  3  3  -0  1  4  6  New Mexico  §  -0  2  6  5  -0  1  3  5  -0  1  7  2  Utah  -0  1  1  7  -0  1  3  12  -0  1  5  12  Wyoming  §  -0  1  2  3  -0  0  ---0  1  2  2  Pacific  2  5  10  253  90  5  3  10  159  169  1  5  19  240  226  Alaska  -0  2  5  10  -0  2  6  2  -0  2  5  1  California  2  3  10  196  71  5  2  8  119  120  1  3  19  169  164  Hawaii  N  0  0  N  N  -0  1  3  2  -0  1  5  10  Oregon  §  -1  4  41  6  -0  2  4  17  -1  3  37  29  Washington  -0  7  11  3  -0  3  27  28  -0  5  24  22  American Samoa  N -0-0  0  -6  -0  1  5  4  Oklahoma  -0  21  53  49  -0  32  36  45  -0  132  170  53  Texas  †  -22  179  1,247  822  -0  12  2  941  -1  8  42  39  Mountain  6  15  37  729  1,047  -1  8  76  97  -0  4  38  36  Arizona  1  3  10  188  204  N  0  0  N  N  -0  2  16  10  Colorado  2  3  8  142  289  -0  0  ---0  1  1  3  Idaho  †  -0  5  29  44  -0  0  -12  -0  1  1  4  Montana  †  -1  11  83  46  -0  2  9  21  -0  1  3  1  Nevada  †  -0  7  19  37  -0  4  5  13  -0  2  2  -New Mexico  †  -1  8  54  73  -0  3  25  15  -0  1  2  5  Utah  3  4  27  198  331  -0  6  13  16  -0  1  3  -Wyoming  †  -0  2  16  23  -0  3  24  20  -0  2  10  13  Pacific  12  24  303  1,176  921  2  3  13  188  234  -0  1  4  3  Alaska  8  3  21  233  86  -0  4  14  43  N  0  0  N  N  California  1  8  129  383  430  2  3  12  160  179  -0  1  1  1  Hawaii  -0  2  16  18  -0  0  --N  0  0  N  N  Oregon  †  -3  10  159  115  -0  4  14  12  -0  1  3  2  Washington  3  6  169  385  272  -0 N  0  0  N  N  N  0  0  N  N  -8  17  414530  503  Oklahoma  N  0  0  N  N  N  0  0  N  N  -1  5  54  64  Texas  §  -0  0  ---0  0  ---25  48  1,228  1,104  Mountain  1  1  7  38  58  -0  2  6  14  3  9  17  410  503  Arizona  -0  0  ---0  0  ---4  12  200  282  Colorado  -0  0  ---0  0  ---2  7  91  51  Idaho Table I . § Not notifiable in all states. Data from states where the condition is not notifiable are excluded from this table, except in 2007 for the domestic arboviral diseases and influenzaassociated pediatric mortality, and in 2003 for SARS-CoV. Reporting exceptions are available at http://www.cdc.gov/epo/dphsi/phs/infdis.htm. ¶ Contains data reported through the National Electronic Disease Surveillance System (NEDSS).
